1. Home
  2. SFBS vs ACAD Comparison

SFBS vs ACAD Comparison

Compare SFBS & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ServisFirst Bancshares Inc.

SFBS

ServisFirst Bancshares Inc.

HOLD

Current Price

$38.69

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$19.82

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFBS
ACAD
Founded
2005
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.4B
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
SFBS
ACAD
Price
$38.69
$19.82
Analyst Decision
Buy
Buy
Analyst Count
3
20
Target Price
★ $46.33
$30.53
AVG Volume (30 Days)
590.0K
★ 2.2M
Earning Date
10-19-2026
11-04-2026
Dividend Yield
★ 1.93%
N/A
EPS Growth
21.63
★ 69.12
EPS
★ 3.09
0.20
Revenue
N/A
★ $726,437,000.00
Revenue This Year
$20.42
$18.71
Revenue Next Year
$9.87
$12.44
P/E Ratio
★ $12.72
$95.58
Revenue Growth
N/A
★ 40.45
52 Week Low
$37.51
$18.39
52 Week High
$92.08
$30.96

Technical Indicators

Market Signals
Indicator
SFBS
ACAD
Relative Strength Index (RSI) 31.00 31.56
Support Level $37.51 N/A
Resistance Level $88.63 $22.92
Average True Range (ATR) 0.93 0.58
MACD 0.88 0.17
Stochastic Oscillator 38.88 56.80

Price Performance

Historical Comparison
SFBS
ACAD

About SFBS ServisFirst Bancshares Inc.

Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: